[go: up one dir, main page]

CL2013003140A1 - Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. - Google Patents

Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.

Info

Publication number
CL2013003140A1
CL2013003140A1 CL2013003140A CL2013003140A CL2013003140A1 CL 2013003140 A1 CL2013003140 A1 CL 2013003140A1 CL 2013003140 A CL2013003140 A CL 2013003140A CL 2013003140 A CL2013003140 A CL 2013003140A CL 2013003140 A1 CL2013003140 A1 CL 2013003140A1
Authority
CL
Chile
Prior art keywords
binds
amino acid
acid sequence
binding fragment
monoclonal antibody
Prior art date
Application number
CL2013003140A
Other languages
English (en)
Inventor
Anita Kavlie
Wayne R Gombotz
James Brian Parent
Clark Tedford
Urs Beat Hagemann
Herald Reiersen
Sergej Kiprijanov
Thomas Dudler
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of CL2013003140A1 publication Critical patent/CL2013003140A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un anticuerpo monoclonal humano aislado o fragmento de unión a antígeno del mismo que se une a MASP-2 humana que comprende : i) una región variable de cadena pesada que comprende las secuencias CDRH1-3 y ii) una región variable de cadena ligera que comprende CDRL1-3, en donde CDRH1 comprende la secuencia de aminoácidos SEQ 28, CDRH2 comprende la secuencia de aminoácidos SEQ 32, CDRH3 comprende la secuencia de aminoácidos SEQ 90 en donde X en la posición 8 es A o R y en donde, CDRL1 comprende la secuencia de aminoácidos SEQ 91 en donde X es la posición 8 es F o Y , CDRL2 comprende la secuencia de aminoácidos SEQ 93 en donde X es la posición 2 es N o K Y X en la posición 3 es K o Q y CDRL3 comprende la secuencia de aminoácidos SEQ 51 en donde el anticuerpo aislado inhibe la activación del complemento dependiente de MASP-2
CL2013003140A 2011-05-04 2013-10-30 Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. CL2013003140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161482567P 2011-05-04 2011-05-04

Publications (1)

Publication Number Publication Date
CL2013003140A1 true CL2013003140A1 (es) 2014-05-23

Family

ID=47090380

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003140A CL2013003140A1 (es) 2011-05-04 2013-10-30 Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.

Country Status (26)

Country Link
US (6) US9011860B2 (es)
EP (2) EP2704743B1 (es)
JP (6) JP5891298B2 (es)
KR (3) KR102024016B1 (es)
CN (2) CN107011443B (es)
AU (1) AU2012250627B2 (es)
BR (1) BR112013028429B1 (es)
CA (3) CA3131223C (es)
CL (1) CL2013003140A1 (es)
CY (1) CY1123212T1 (es)
DK (1) DK2704743T3 (es)
ES (1) ES2795667T3 (es)
HR (1) HRP20200887T1 (es)
HU (1) HUE049154T2 (es)
IL (4) IL229208B (es)
LT (1) LT2704743T (es)
ME (1) ME03755B (es)
MX (3) MX347691B (es)
PL (1) PL2704743T3 (es)
PT (1) PT2704743T (es)
RS (1) RS60541B1 (es)
RU (3) RU2636038C2 (es)
SI (1) SI2704743T1 (es)
SM (1) SMT202000294T1 (es)
WO (1) WO2012151481A1 (es)
ZA (1) ZA201308943B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012139081A2 (en) 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
LT2914291T (lt) 2012-11-02 2022-06-10 Bioverativ Usa Inc. Antikūnai prieš komplemento c1s ir jų panaudojimo būdai
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
WO2014144542A2 (en) * 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
KR102677379B1 (ko) * 2013-10-17 2024-06-24 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
IL259225B (en) 2015-11-09 2022-09-01 Omeros Corp Compositions comprising masp-2 inhibitory antibodies and antigen-binding fragments thereof for use in treating tma assoiated with hematopoietic stem cell transplantation
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
IL294411B2 (en) 2016-01-05 2025-10-01 Omeros Corp MASP-2 inhibitors for use in suppressing fibrosis
MA44518A (fr) 2016-03-31 2019-02-06 Omeros Corp Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
PL3525583T3 (pl) 2016-10-12 2026-01-19 Bioverativ Usa Inc. Przeciwciała anty-c1s i sposoby ich zastosowania
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TW202529812A (zh) 2017-08-15 2025-08-01 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
CN111278863A (zh) * 2017-08-25 2020-06-12 奥默罗斯公司 高浓缩低粘度masp-2抑制性抗体制剂、试剂盒和治疗患有非典型溶血综合征的受试者的方法
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN119350433A (zh) * 2018-05-29 2025-01-24 奥默罗斯公司 Masp-2抑制剂和使用方法
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
KR20250030005A (ko) * 2018-12-13 2025-03-05 아르제넥스 비브이 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법
IL293363A (en) * 2019-11-26 2022-07-01 Omeros Corp Masp-2 inhibitors for use in treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
TWI867422B (zh) * 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN114634575B (zh) * 2020-12-16 2025-04-11 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
EP4288098A4 (en) * 2021-02-05 2025-04-02 Omeros Corporation BIOMARKERS FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CA3216034A1 (en) 2021-04-25 2022-11-03 Xiaofeng Yang Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
BR112023025596A2 (pt) * 2021-06-08 2024-02-27 Jiangxi Jemincare Group Co Ltd Anticorpo anti-masp-2 e uso do mesmo
CN117616042A (zh) * 2021-06-30 2024-02-27 苏州创胜医药集团有限公司 新的抗masp-2抗体
WO2023103789A1 (zh) * 2021-12-10 2023-06-15 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
WO2023108028A2 (en) * 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116284412A (zh) * 2021-12-21 2023-06-23 沈阳三生制药有限责任公司 一种抗masp-2抗体及其制备方法与用途
WO2023173036A2 (en) 2022-03-10 2023-09-14 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
JP2025525363A (ja) * 2022-03-18 2025-08-05 インマージーン プライベート リミテッド Ｍａｓｐ－２を標的とする抗体及びその使用
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
EP4643878A2 (en) 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
US12216123B2 (en) 2023-04-25 2025-02-04 Nuvance Health Extracellular vesicle derived MASP-2 directed cancer treatment methods
WO2024230836A1 (zh) 2023-05-11 2024-11-14 大睿生物 调控MASP2基因活性的dsRNA分子
WO2024251199A1 (zh) 2023-06-09 2024-12-12 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP1140171A4 (en) 1998-12-15 2002-03-13 Brigham & Womens Hospital METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM
CA2378880C (en) 1999-07-21 2010-02-23 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20010051754A1 (en) 1999-08-03 2001-12-13 Daria N. Lissy Plural stage toluene disproportionation process minimizing ethylbenzene
WO2001064751A2 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
WO2002006460A2 (en) * 2000-07-13 2002-01-24 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
DE60128914T2 (de) 2001-10-05 2008-05-08 Affimed Therapeutics Ag Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
EP1461442B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
KR101101261B1 (ko) 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
CA2515389A1 (en) * 2003-02-28 2004-09-10 Mitsubishi Pharma Corporation Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical compostion, and diagnostic reagent
DK2374819T3 (en) * 2003-05-12 2017-06-06 Helion Biotech Aps Antibodies against MASP-2
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2446900T3 (en) * 2004-06-10 2017-07-10 Omeros Corp Methods for treating conditions associated with MASP-2-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
JP5882058B2 (ja) * 2008-11-07 2016-03-09 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
HUE030897T2 (en) 2009-10-16 2017-06-28 Omeros Corp Procedures for Treatment of Disseminated Intravascular Coagulation by Inhibition of MASP-Dependent Complement Activation
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
IN2014KN02324A (es) * 2012-04-06 2015-05-01 Omeros Corp

Also Published As

Publication number Publication date
JP2024170616A (ja) 2024-12-10
HRP20200887T1 (hr) 2020-09-04
CN107011443B (zh) 2021-04-30
US9011860B2 (en) 2015-04-21
CA2832871A1 (en) 2012-11-08
EP2704743A4 (en) 2014-11-05
US20120282263A1 (en) 2012-11-08
JP2020097630A (ja) 2020-06-25
MX361175B (es) 2018-11-29
CN107011443A (zh) 2017-08-04
SMT202000294T1 (it) 2020-07-08
RU2013153527A (ru) 2015-06-10
IL266756B (en) 2021-08-31
HUE049154T2 (hu) 2020-09-28
IL229208B (en) 2021-03-25
JP2018123148A (ja) 2018-08-09
JP6669800B2 (ja) 2020-03-18
PL2704743T3 (pl) 2020-08-24
KR20160087917A (ko) 2016-07-22
US9475885B2 (en) 2016-10-25
EP3725811A3 (en) 2021-01-27
EP2704743B1 (en) 2020-03-11
AU2012250627B2 (en) 2016-01-07
MX2018014714A (es) 2021-11-16
KR20180086298A (ko) 2018-07-30
IL229208A0 (en) 2014-01-30
CN103687620B (zh) 2017-10-13
CA3131223A1 (en) 2012-11-08
IL285522A (en) 2021-09-30
AU2012250627A1 (en) 2013-03-21
US20190119402A1 (en) 2019-04-25
RU2017137872A3 (es) 2019-04-30
US20170088632A1 (en) 2017-03-30
RU2636038C2 (ru) 2017-11-17
PT2704743T (pt) 2020-06-17
ME03755B (me) 2021-04-20
NZ715226A (en) 2017-07-28
ES2795667T3 (es) 2020-11-24
US11613589B2 (en) 2023-03-28
EP3725811A2 (en) 2020-10-21
CY1123212T1 (el) 2021-10-29
RU2017137872A (ru) 2019-04-30
CA3131223C (en) 2024-01-30
NZ617487A (en) 2016-03-31
RU2020120539A (ru) 2021-12-23
EP2704743A1 (en) 2014-03-12
LT2704743T (lt) 2020-09-10
JP2015227380A (ja) 2015-12-17
MX347691B (es) 2017-05-09
DK2704743T3 (en) 2020-05-25
US20160002349A1 (en) 2016-01-07
JP2022172275A (ja) 2022-11-15
CA2832871C (en) 2019-01-15
US20240092938A1 (en) 2024-03-21
RU2725958C2 (ru) 2020-07-07
KR101882830B1 (ko) 2018-07-31
ZA201308943B (en) 2015-05-27
US20210054099A1 (en) 2021-02-25
BR112013028429B1 (pt) 2022-11-08
SI2704743T1 (sl) 2020-08-31
US10683367B2 (en) 2020-06-16
US10047165B2 (en) 2018-08-14
NZ733310A (en) 2021-12-24
JP2014515922A (ja) 2014-07-07
CN103687620A (zh) 2014-03-26
CA3025762C (en) 2021-11-09
JP6352226B2 (ja) 2018-07-04
RS60541B1 (sr) 2020-08-31
CA3025762A1 (en) 2012-11-08
WO2012151481A1 (en) 2012-11-08
JP5891298B2 (ja) 2016-03-22
IL266756A (en) 2019-07-31
BR112013028429A2 (pt) 2020-07-21
MX2013012862A (es) 2013-12-02
KR102024016B1 (ko) 2019-11-04
KR20140006096A (ko) 2014-01-15
KR101641057B1 (ko) 2016-07-20

Similar Documents

Publication Publication Date Title
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
NZ610153A (en) Novel anti-dr5 antibody
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
MX2020013068A (es) Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
JP2020500538A5 (es)
PE20170687A1 (es) Proteinas de enlace a cd127
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
RU2017104813A (ru) Молекулы со специфичностью к cd45 и cd79
NZ602621A (en) Antibodies against csf-1r
PE20161033A1 (es) Proteinas de union al antigeno gitr
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
RU2021103288A (ru) МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22
NZ603972A (en) Anti-fgfr2 antibodies
PE20161439A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
PE20221151A1 (es) Anticuerpos anti-cd96 y sus metodos de uso
AR082194A1 (es) Anticuerpos anti-ron
PE20181051A1 (es) Anticuerpo anti-epha4